{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:50:01Z","timestamp":1780937401508,"version":"3.54.1"},"posted":{"date-parts":[[2023,5,10]]},"group-title":"In Review","reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,21]]},"abstract":"<title>Abstract<\/title>\n        <p>Background\n Treatment of cystic fibrosis (CF) has been revolutionized by the use of cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators such as elexacaftor\/tezacaftor\/ivacaftor (ETI) triple therapy. Prior studies support a role for type 2 (T2) inflammation in many people with CF (PwCF) and CF-asthma overlap syndrome (CFAOS) is considered a separate clinical entity. It is unknown whether initiation of ETI therapy impacts T2 inflammation in PwCF. We hypothesized that ETI initiation decreases T2 inflammation in PwCF.\nMethods\n A single center retrospective chart review was conducted for adult PwCF. As markers of T2 inflammation, absolute eosinophil count (AEC) and total immunoglobulin E (IgE) data were collected longitudinally 12 months prior to ETI therapy initiation and 12 months following therapy initiation. Multivariable analyses adjusted for the age, gender, CFTR mutation, disease severity, inhaled steroid use, and microbiological colonization.\nResults\n There was a statistically significant reduction (20.10%, p\u2009&lt;\u20090.001) in 12-month mean IgE following ETI initiation; this change remained statistically significant in the multivariate model. The longitudinal analysis demonstrated no change in AEC following therapy initiation.\nConclusion\n This study shows reduction in IgE but no change in AEC after ETI therapy initiation. We think that the lack of influence on AEC argues against an impact on previously established T2 inflammation and that the reduction in IgE is likely related to antigen load reduction post ETI. Further studies are warranted to determine the underlying mechanism of ETI impact on T2 inflammation and possible role for asthma immunomodulator therapy post ETI initiation in CFAOS.<\/p>","DOI":"10.21203\/rs.3.rs-2846739\/v1","type":"posted-content","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:40:28Z","timestamp":1683776428000},"source":"Crossref","is-referenced-by-count":2,"title":["The Impact of CFTR Modulator Triple Therapy on Type 2 Inflammatory Response in Patients with Cystic Fibrosis"],"prefix":"10.21203","author":[{"given":"Ajay","family":"Mehta","sequence":"first","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lee","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galvin","family":"Li","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Jones","sequence":"additional","affiliation":[{"name":"University of Virginia Department of Public Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Hanson","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lonabaugh","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"List","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Borish","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-3247","authenticated-orcid":false,"given":"Dana","family":"Albon","sequence":"additional","affiliation":[{"name":"University of Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo J","year":"2022","unstructured":"Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(3):456\u2013462. doi:10.1016\/j.jcf.2022.01.009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9678","key":"ref2","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan BP","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD. Cystic fibrosis. The Lancet. 2009;373(9678):1891\u20131904. doi:10.1016\/S0140-6736(09)60327-5","journal-title":"The Lancet"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/thx.49.5.496","article-title":"Eosinophilic activation in cystic fibrosis","volume":"49","author":"Koller DY","year":"1994","unstructured":"Koller DY, Gotz M, Eichler I, Urbanek R. Eosinophilic activation in cystic fibrosis. Thorax. 1994;49(5):496\u2013499. doi:10.1136\/thx.49.5.496","journal-title":"Thorax"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1164\/ajrccm.152.2.7633718","article-title":"Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis","volume":"152","author":"Koller DY","year":"1995","unstructured":"Koller DY, Urbanek R, G\u00f6tz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med. 1995;152(2):629\u2013633. doi:10.1164\/ajrccm.152.2.7633718","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla ME","year":"2019","unstructured":"Kuruvilla ME, Lee FEH, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinic Rev Allerg Immunol. 2019;56(2):219\u2013233. doi:10.1007\/s12016-018-8712-1","journal-title":"Clinic Rev Allerg Immunol"},{"key":"ref6","doi-asserted-by":"publisher","author":"Siedlecki A","unstructured":"Siedlecki A, Quon B, Tebbutt SJ, Dorscheid DR. Evaluating Peripheral Blood Eosinophilia and Health Outcomes in Hospitalized Cystic Fibrosis Patients with Pulmonary Exacerbations. Published online 2019:A6177-A6177. doi:10.1164\/ajrccm-conference.2019.199.1_meetingabstracts.a6177","DOI":"10.1164\/ajrccm-conference.2019.199.1_meetingabstracts.a6177"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13223-023-00760-z","article-title":"Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization","volume":"19","year":"2023","unstructured":"<background-color:#BCBCBC;display:none;>Albon<\/background-color:#BCBCBC;display:none;><display:none;><\/display:none;><background-color:#DDDDDD;display:none;>D<\/background-color:#DDDDDD;display:none;><vertical-align:sub;>,<\/vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#BCBCBC;vertical-align:sub;>Zhang<\/background-color:#BCBCBC;vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#DDDDDD;vertical-align:sub;>L<\/background-color:#DDDDDD;vertical-align:sub;><vertical-align:sub;>,<\/vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#BCBCBC;vertical-align:sub;>Patrie<\/background-color:#BCBCBC;vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#DDDDDD;vertical-align:sub;>J<\/background-color:#DDDDDD;vertical-align:sub;><vertical-align:sub;>,<\/vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#BCBCBC;vertical-align:sub;>Jones<\/background-color:#BCBCBC;vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#DDDDDD;vertical-align:sub;>M<\/background-color:#DDDDDD;vertical-align:sub;><vertical-align:sub;>,<\/vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#BCBCBC;vertical-align:sub;>Li<\/background-color:#BCBCBC;vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#DDDDDD;vertical-align:sub;>ZG<\/background-color:#DDDDDD;vertical-align:sub;><vertical-align:sub;>,<\/vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#BCBCBC;vertical-align:sub;>Noonan<\/background-color:#BCBCBC;vertical-align:sub;><vertical-align:sub;> <\/vertical-align:sub;><background-color:#DDDDDD;vertical-align:sub;>E<\/background-color:#DDDDDD;vertical-align:sub;><vertical-align:sub;>,<\/vertical-align:sub;> et al. Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization. Allergy Asthma Clin Immunol. 2023;19(1):15. doi:10.1186\/s13223-023-00760-z","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13223-019-0397-3","article-title":"Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series","volume":"6","author":"Zhang L","unstructured":"Zhang L, Borish L, Smith A, Somerville L, Albon D. Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series. Allergy Asthma Clin Immunol. 2020 Jan 6;16:3. doi: 10.1186\/s13223-019-0397-3. PMID: 31921321; PMCID: PMC6945791.","journal-title":"Allergy Asthma Clin Immunol. 2020 Jan"},{"key":"ref9","volume-title":"Registry 2021 Annual Data Report","author":"Cystic Fibrosis Foundation Patient","year":"2022","unstructured":"Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report. Cystic Fibrosis Foundation; 2022."},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00985-7","article-title":"Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome","volume":"21","author":"Marion CR","year":"2021","unstructured":"Marion CR, Izquierdo M, Hanes HC, Barrios C. Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome. Current Allergy and Asthma Reports. 2021;21(2). doi:10.1007\/s11882-020-00985-7","journal-title":"Current Allergy and Asthma Reports"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols DP","year":"2022","unstructured":"Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD et al. Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022;205(5):529\u2013539. doi:10.1164\/rccm.202108-1986OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates D","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Soft. 2015;67(1). doi:10.18637\/jss.v067.i01","journal-title":"J Stat Soft"},{"issue":"13","key":"ref13","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: Tests in Linear Mixed Effects Models","volume":"82","author":"Kuznetsova A","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: Tests in Linear Mixed Effects Models. J Stat Soft. 2017;82(13). doi:10.18637\/jss.v082.i13","journal-title":"J Stat Soft"},{"key":"ref14","article-title":"Estimated Marginal Means, aka Least-Squares Means_. R package version 1.8.2","author":"Lenth R","unstructured":"Lenth R. _emmeans: Estimated Marginal Means, aka Least-Squares Means_. R package version 1.8.2. Published online 2022. https:\/\/CRAN.R-project.org\/package=emmeans"},{"issue":"5","key":"ref15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper Type 2\u2013driven Inflammation Defines Major Subphenotypes of Asthma","volume":"180","author":"Woodruff PG","year":"2009","unstructured":"Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al. T-helper Type 2\u2013driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009;180(5):388\u2013395. doi:10.1164\/rccm.200903-0392OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse WW","year":"2021","unstructured":"Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2):2003393. doi:10.1183\/13993003.03393-2020","journal-title":"Eur Respir J"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.696","article-title":"Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis","volume":"9","author":"Boyle M","year":"2021","unstructured":"Boyle M, Mulrennan S, Morey S, Vekaria S, Popowicz N, Tai A. Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis. Respirology Case Reports. 2021;9(1). doi:10.1002\/rcr2.696","journal-title":"Respirology Case Reports"},{"issue":"8","key":"ref18","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.4049\/jimmunol.177.8.5186","article-title":"Aspergillus fumigatus Generates an Enhanced Th2-Biased Immune Response in Mice with Defective Cystic Fibrosis Transmembrane Conductance Regulator","volume":"177","author":"Allard JB","year":"2006","unstructured":"Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA. Aspergillus fumigatus Generates an Enhanced Th2-Biased Immune Response in Mice with Defective Cystic Fibrosis Transmembrane Conductance Regulator. J Immunol. 2006;177(8):5186\u20135194. doi:10.4049\/jimmunol.177.8.5186","journal-title":"J Immunol"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5863\/1551-6776-17.1.88","article-title":"Management of Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis Using Anti-Immunoglobulin E Therapy (Omalizumab)","volume":"17","author":"ElMallah MK","year":"2012","unstructured":"ElMallah MK, Hendeles L, Hamilton RG, Capen C, Schuler PM. Management of Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis Using Anti-Immunoglobulin E Therapy (Omalizumab). The Journal of Pediatric Pharmacology and Therapeutics. 2012;17(1):88\u201392. doi:10.5863\/1551-6776-17.1.88","journal-title":"The Journal of Pediatric Pharmacology and Therapeutics"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/genes10121036","article-title":"High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates","volume":"10","author":"Fischer AJ","year":"2019","unstructured":"Fischer, A.J.; Kilgore, S.H.; Singh, S.B.; Allen, P.D.; Hansen, A.R.; Limoli, D.H, et al. High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates. Genes. 2019;10(12):1036. doi:10.3390\/genes10121036","journal-title":"Genes"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2846739\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2846739\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T12:45:57Z","timestamp":1697546757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2846739\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":20,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2846739\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13223-023-00822-2","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,5,10]]},"subtype":"preprint"}}